AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol

This article originally appeared here.
Share this content:
AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol
AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol

TUESDAY, Nov. 15, 2016 (HealthDay News) -- A new injectable medication called inclisiran cuts low-density lipoprotein (LDL) cholesterol by half or more, and the effect could last for four to six months, according to research presented at the annual meeting of the American Heart Association, held from Nov. 12 to 16 in New Orleans.

Inclisiran is a next-level PCSK9 inhibitor, which works on a genetic level to prevent cells from producing PCSK9, study presenter Kausik Ray, M.D., of Imperial College London, told HealthDay. The inclisiran clinical trial involved 501 patients who were assigned to either a control group or one of four groups that received different doses of the drug.

One dose of inclisiran at 300 mg or greater caused a 51 percent drop in LDL cholesterol that lasted at least 90 days, while two doses caused a 57 percent reduction that lasted up to six months, Ray reported. Based on these results, Ray and his colleagues estimate patients would only need an inclisiran injection two or three times a year to control their cholesterol.

Side effects from the medication were similar to those reported by patients taking either statins or placebos, the researchers reported. Muscle aches, headache, fatigue, back pain, high blood pressure, diarrhea, and dizziness were the most common side effects.

The study was funded by The Medicines Company, the manufacturer of inclisiran.

Abstract
More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Cracks Down on Kratom Products

FDA Cracks Down on Kratom Products

Missouri-based Divinity Products Distribution will recall and destroy kratom-containing products

Kurtosis Diffusion-Weighted Imaging Helps ID Breast Lesions

Kurtosis Diffusion-Weighted Imaging Helps ID Breast Lesions

Radiomics feature model reduced false positives, with benefit seen for BI-RADS 4a, 4b lesions

is free, fast, and customized just for you!

Already a member?

Sign In Now »